incretin and glp-1 The system: glucagon-like peptide-1 receptor agonists dipeptidyl peptidase-4 inhibitors in type 2 diabetes GIP and GLP-1 as incretin

2017;96(14):e6558

Standard U-100 insulin syringes (1 mL with 100 unit markings) pair perfectly with the calculator output

At the end of the study, the women who received the GLP-1 agonist had lost an average of 4.9 kg (10.8 lbs) and had significant improvements in insulin resistance, fasting glucose, and cholesterol levels

The purpose of this review was to provide a brief account of these developments and to discuss the possible mechanisms involved

Adequate fluid intake supports digestion and helps offset common side effects like constipation

GLP-1 and GIP receptor activation produces gastrointestinal effects (nausea, reduced appetite) that are dose-dependent